Prof Xavier Leleu speaks to ecancer about the updates from the IMROZ and BENEFIT studies at ASCO 2024. The IMROZ study compared the effectiveness of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) with VRd in newly diagnosed multiple myeloma patients who are not eligible for transplant.

The results showed that Isa-VRd significantly reduced the risk of disease progression or death compared to VRd and produced deep and sustained responses. Prof Leleu mentions that these findings suggest that Isa-VRd could be a new standard of care for patients not intended for transplant.

The BENEFIT study evaluated the combination of isatuximab, lenalidomide, and dexamethasone with bortezomib, comparing it to a regimen containing lenalidomide and bortezomib in patients with newly diagnosed multiple myeloma who are not eligible for a transplant. Isa-VRd significantly improved responses, including a substantial increase in the rate of minimal residual disease (MRD) negativity compared to IsaRd.

Prof Leleu says that this study provides support for considering Isa-VRd as a new standard of care for non-frail patients with newly diagnosed multiple myeloma who are not eligible for a transplant.